---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013417"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:58:22.230552+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma enters ATM equity offering with Citizens JMP Securities

## Summary
- Agreement allows at-the-market sales of common stock; 3% commission to Agent.
- Sales conducted under existing S-3 shelf (File No. 333-269100), filed January 2023.
- No immediate sale; company controls timing, price, and size of any offerings.
- Agent indemnified and reimbursed up to $50,000 for specified expenses.
- Shares subject to registration limits and Nasdaq rules.

## SEC filing metadata
- accession: 0001641172-25-013417
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000164117225013417/0001641172-25-013417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000164117225013417/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013417
- JSON: https://secwatch.observer/filing/0001641172-25-013417.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.